<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ojrdrt</journal-id><journal-title-group><journal-title xml:lang="ru">Онкологический журнал: лучевая диагностика, лучевая терапия</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of oncology: diagnostic radiology and radiotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7593</issn><issn pub-type="epub">2713-167X</issn><publisher><publisher-name>НЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37174/2587-7593-2023-6-4-34-41</article-id><article-id custom-type="elpub" pub-id-type="custom">ojrdrt-327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛУЧЕВАЯ ДИАГНОСТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>DIAGNOSTIC RADIOLOGY</subject></subj-group></article-categories><title-group><article-title>Радиомические характеристики различных биотипов рака молочной железы стадии T1</article-title><trans-title-group xml:lang="en"><trans-title>Radiomic Characteristics of Different T1  Breast Cancer Biotypes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-4753-2463</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>A. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алиса Юрьевна Попова, заведующая отделением</p><p>отделение лучевой диагностики</p><p>620036</p><p>ул. Соболева, 29</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>620036</p><p>29, Soboleva str.</p><p>Yekaterinburg</p></bio><email xlink:type="simple">mrs.alisapopova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4742-9157</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гажонова</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Gazhonova</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вероника Евгеньевна Гажонова, д. м. н., профессоp</p><p>кафедра рентгенологии и ультразвуковой диагностики</p><p>121359</p><p>ул. Маршала Тимошенко, 19, стр. 1А</p><p>Москва</p></bio><bio xml:lang="en"><p>121359</p><p>19a, bld. 1А, Marshala Timoshenko str.</p><p>Moscow</p></bio><email xlink:type="simple">vx969@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демидов</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Demidov</surname><given-names>S. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Михайлович Демидов, д. м. н., заведующий кафедрой, профессор</p><p>кафедра онкологии и лучевой диагностики</p><p>620028</p><p>ул. Репина, 3</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>20028</p><p>63, Repin str.</p><p>Yekaterinburg</p></bio><email xlink:type="simple">professordemidov@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6212-0495</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казанцева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazanceva</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наталья Владимировна Казанцева, заведующая отделением</p><p>патологоанатомическое отделение</p><p>620036</p><p>ул. Соболева, 29</p><p>Екатеринбург</p></bio><bio xml:lang="en"><p>620036</p><p>29, Soboleva str.</p><p>Yekaterinburg</p></bio><email xlink:type="simple">nvkazantseva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Свердловский областной онкологический диспансер</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sverdlovsk Regional Oncology Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Центральная государственная медицинская академия управления делами Президента РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central State Medical Academy Management Department of the President of Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Уральский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Urals State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>12</month><year>2023</year></pub-date><volume>6</volume><issue>4</issue><fpage>34</fpage><lpage>41</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Попова А.Ю., Гажонова В.Е., Демидов С.М., Казанцева Н.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Попова А.Ю., Гажонова В.Е., Демидов С.М., Казанцева Н.В.</copyright-holder><copyright-holder xml:lang="en">Popova A.Y., Gazhonova V.E., Demidov S.M., Kazanceva N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.oncoradjournal.ru/jour/article/view/327">https://www.oncoradjournal.ru/jour/article/view/327</self-uri><abstract><sec><title>   Введение</title><p>   Введение: Рак молочной железы (РМЖ) занимает лидирующие позиции среди онкологических заболеваний, выявляемых у женщин. Диагностика и поиск предикторов злокачественных новообразований с использованием лучевых и молекулярно-генетических методов исследований позволяет своевременно поставить диагноз и назначить лечение, что улучшает прогноз при РМЖ.</p></sec><sec><title>   Цель</title><p>   Цель: Выявление корреляции между молекулярным подтипом опухоли РМЖ на ранней клинической стадии и паттернами маммографического метода.</p></sec><sec><title>   Методы</title><p>   Методы: Проспективное одноцентровое исследование 363 пациенток с диагнозом РМЖ, наблюдаемых в течение 2021 г. Проведена рентгеновская маммография в двух проекциях, трепанобиопсия под ультразвуковым контролем для гистологической верификации и иммуногистохимический (ИГХ) анализ для определения молекулярных подтипов.</p></sec><sec><title>   Результаты</title><p>   Результаты: Выявлены статистически значимые различия по возрасту между люминальным А, люминальным ВHER2+ (p &lt; 0,001) и трижды негативным (p = 0,037) подтипами; между люминальным В, люминальным ВHER2+ (p = 0,001) и трижды негативным (p = 0,046) подтипами; между люминальным ВHER2+ и нелюминальным HER2+ (p = 0,002) подтипами; между нелюминальным HER2+ и трижды негативным (p = 0,034) подтипами. При сравнении структуры рентгенологической плотности выявлены статистически значимые различия между люминальным В, люминальным ВHER2+ (p = 0,010) и трижды негативным (p = 0,010) подтипами; между люминальным А и трижды негативным (p = 0,010) подтипами. При сравнении ведущего маммографического симптома (p &lt; 0,001), рентгенологических контуров образования (p &lt; 0,001), плотности патологических изменений (p &lt; 0,001), размера, впервые выявленного патологического процесса (p &lt; 0,001) в подгруппах были также найдены статистически значимые различия. Отмечено разделение на группы по размерам патологических изменений внутри биотипов, где агрессивные фенотипы трижды негативного подтипа (p = 0,001), нелюминальный HER2+ (p = 0,02) и люминальный В (p = 0,02) в отличие от люминального А проявились большей протяженностью максимального линейного размера опухоли. Описан симптом втяжения соска (p = 0,048), который не был свойственным для трижды негативного и нелюминального HER2 подтипов.</p></sec><sec><title>   Выводы</title><p>   Выводы: Особенности рентгенологических проявлений РМЖ размерами до 20 мм могут являться предикторами молекулярных подтипов. При выявлении явных расхождений ИГХ подтипа опухоли и рентгенографических проявлений опухоли необходимо до начала лечения выполнить повтоp ИГХ анализа операционного материала.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>   Background</title><p>   Background: Breast cancer (BC) occupies a leading position among my oncological diseases detected in women. Identification and search for predictors of malignant neoplasms using radiation and molecular genetic methods of research allows timely diagnosis and treatment, which improves the prognosis for breast cancer.</p></sec><sec><title>   Purpose</title><p>   Purpose: To identify a correlation between the molecular subtype of a breast cancer tumor at an early clinical stage and the patterns of the mammographic method.</p></sec><sec><title>   Methods</title><p>   Methods: A prospective, single-center study of 363 patients diagnosed with breast cancer followed up during 2021. X-ray mammography in two projections, ultrasound-guided trephine biopsy for histological verification, and immunohistochemical (IHC) analysis to determine molecular subtypes were performed.</p></sec><sec><title>   Results</title><p>   Results: There were statistically significant differences in age between subtypes luminal A, luminal BHER2+ (p &lt; 0.001) and triple negative (p = 0.037), luminal B, luminal BHER2+ (p = 0.001) and triple negative (p = 0.046), luminal BHER2+ and nonluminal HER2+ (p = 0.002), between nonluminal HER2+ and triple negative subtype (p = 0.034). When comparing the structure of radiological density, statistically significant differences were revealed between the subgroups luminal B, luminal BHER2+ (p = 0.010) and triple negative (p = 0.010), between luminal A and triple negative subtypes (p = 0.010). When comparing the leading mammographic symptom (p &lt; 0.001), radiological contours of the formation (p &lt; 0.001), the density of pathological changes (p &lt; 0.001), the size, the newly detected pathological process (p &lt; 0.001) statistically significant differences were also found in the subgroups. A division into groups according to the size of pathological changes within the biotypes was noted, where the aggressive phenotypes of the triple negative subtype (p = 0.001), non-luminal HER2+ (p = 0.02) and luminal B (p = 0.02), in contrast to luminal A, were manifested by a greater extent. the maximum linear size of the tumor. A symptom of nipple retraction (p = 0.048) was described, which was not characteristic of triple negative and non-luminal HER2 cancer.</p></sec><sec><title>   Conclusions</title><p>   Conclusions: Visualization features of differences in the radiological manifestation of breast cancer of different biological subtypes up to 20 mm can be predictors of molecular subtypes. Pathological verification and IHC study remain a mandatory study, but it may be necessary to conduct an X-ray histological correlation before starting treatment and, if obvious discrepancies are detected, repeat the IHC analysis from the surgical material.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>Т1</kwd><kwd>маммография</kwd><kwd>радиомика</kwd><kwd>биологические подтипы</kwd><kwd>рентген-гистологическая корреляция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>T1</kwd><kwd>breast cancer</kwd><kwd>mammography</kwd><kwd>radiomics</kwd><kwd>biological subtypes</kwd><kwd>X-ray histological correlation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено без спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The study had no sponsorship</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cancer Today [Интернет]. International agency for research on cancer. Режим доступа: https://gco.iarc.fr/today/home. Дата обращения: 11. 05. 2023.</mixed-citation><mixed-citation xml:lang="en">Cancer Today [The Internet]. International agency for research on cancer. Режим доступа: https://gco.iarc.fr/today/home. Date of application: 11. 05. 2023.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2020 г. Заболеваемость и смертность. Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.</mixed-citation><mixed-citation xml:lang="en">Malignant neoplasms in Russia in 2020 (morbidity and mortality). Eds. Kaprin AD, Starinsky VV, Shakhzadova AO. Moscow. 2021. 252 p. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ginsburg O, Yip C, Brooks A, et al. Breast cancer early detection: A phased approach to implementation. Cancer. 2020;126(Suppl. 10):2379-93. DOI: 10.1002/cncr.32887.</mixed-citation><mixed-citation xml:lang="en">Ginsburg O, Yip C, Brooks A, et al. Breast cancer early detection: A phased approach to implementation. Cancer. 2020;126(Suppl. 10):2379-93. DOI: 10.1002/cncr.32887.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Barba D, León-Sosa A, Lugo P, et al. Breast cancer, screening and diagnostic tools: All you need to know. Crit Rev Oncol Hematol. 2021;157:103174. DOI: 10.1016/j.critrevonc.2020.103174.</mixed-citation><mixed-citation xml:lang="en">Barba D, León-Sosa A, Lugo P, et al. Breast cancer, screening and diagnostic tools: All you need to know. Crit Rev Oncol Hematol. 2021;157:103174. DOI: 10.1016/j.critrevonc.2020.103174.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pesapane F, Suter MB, Rotili A, et al. Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? Med Oncol. 2020;37(Suppl. 4):29. DOI: 10.1007/s12032-020-01353-1.</mixed-citation><mixed-citation xml:lang="en">Pesapane F, Suter MB, Rotili A, et al. Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? Med Oncol. 2020;37(Suppl. 4):29. DOI: 10.1007/s12032-020-01353-1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Vasef MA, Auerbach A. Diagnostic pathology: Molecular Oncology. 2&lt;sup&gt;th&lt;/sup&gt; ed. Philadelphia: Elsevier, 2020.</mixed-citation><mixed-citation xml:lang="en">Vasef MA, Auerbach A. Diagnostic pathology: Molecular Oncology. 2&lt;sup&gt;th&lt;/sup&gt; ed. Philadelphia: Elsevier, 2020.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ma W, Zhao Y, Ji Y, et al. Breast cancer molecular subtype prediction by mammographic radiomic features. Acad Radiol. 2019;26(2):196-201. DOI: 10.1016/j.acra.2018.01.023.</mixed-citation><mixed-citation xml:lang="en">Ma W, Zhao Y, Ji Y, et al. Breast cancer molecular subtype prediction by mammographic radiomic features. Acad Radiol. 2019;26(2):196-201. DOI: 10.1016/j.acra.2018.01.023.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Говорухина ВГ, Семенов СС, Гележе ПБ и др. Роль маммографии в радиомике рака молочной железы. Digital Diagnostics. 2021;2(2):185-99. DOI: 10.17816/DD70479.</mixed-citation><mixed-citation xml:lang="en">Govorukhina VG, Semenov SS, Gelezhe PB, et al. The role of mammography in radiomics of breast cancer. Digital Diagnostics. 2021;2(2):185-99. (In Russian) DOI: 10.17816/DD70479.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shaikh S, Rasheed A. Predicting Molecular Subtypes of Breast Cancer with Mammography and Ultrasound Findings: Introduction of Sono-Mammometry Score. Radiol Res Pract. 2021;9:6691958. DOI: 10.1155/2021/6691958.</mixed-citation><mixed-citation xml:lang="en">Shaikh S, Rasheed A. Predicting Molecular Subtypes of Breast Cancer with Mammography and Ultrasound Findings: Introduction of Sono-Mammometry Score. Radiol Res Pract. 2021;9:6691958. DOI: 10.1155/2021/6691958.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020.;84:106535. DOI: 10.1016/j.intimp.2020.106535.</mixed-citation><mixed-citation xml:lang="en">Barzaman K, Karami J, Zarei Z, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020.;84:106535. DOI: 10.1016/j.intimp.2020.106535.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации: Рак молочной железы. 2021.</mixed-citation><mixed-citation xml:lang="en">Clinical Guidelines: Breast cancer. 2021. (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Acr.org. [Интернет]. Breast Imaging Reporting &amp; Data System (BI-RADS®) Режим доступа: https://acr.org/birads. Дата обращения: 11. 05. 2023.</mixed-citation><mixed-citation xml:lang="en">Acr.org. [The Internet]. Breast Imaging Reporting &amp; Data System (BI-RADS®) Режим доступа: https://acr.org/birads. Date of application: 11. 05. 2023.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li E, Guida JL, Tian Y, et al. Associations between mammographic density and tumor characteristics in Chinese women with breast cancer. Breast Cancer Res Treat. 2019.;177(Suppl. 2);527-36. DOI: 10.1007/s10549-019-05325-6.</mixed-citation><mixed-citation xml:lang="en">Li E, Guida JL, Tian Y, et al. Associations between mammographic density and tumor characteristics in Chinese women with breast cancer. Breast Cancer Res Treat. 2019.;177(Suppl. 2);527-36. DOI: 10.1007/s10549-019-05325-6.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tian Y, Guida JL, Koka H, et al. Quantitative Mammographic Density Measurements and Molecular Subtypes in Chinese Women With Breast Cancer. JNCI Cancer Spectr. 2020;5(Suppl. 1):pkaa092. DOI: 10.1093/jncics/pkaa092.</mixed-citation><mixed-citation xml:lang="en">Tian Y, Guida JL, Koka H, et al. Quantitative Mammographic Density Measurements and Molecular Subtypes in Chinese Women With Breast Cancer. JNCI Cancer Spectr. 2020;5(Suppl. 1):pkaa092. DOI: 10.1093/jncics/pkaa092.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Nie Z, Wang J, Ji XC. Microcalcification-associated breast cancer: HER2-enriched molecular subtype is associated with mammographic features. Br J Radiol. Forthcoming 2021. P. 29:20170942. DOI: 10.1259/bjr.20170942.</mixed-citation><mixed-citation xml:lang="en">Nie Z, Wang J, Ji XC. Microcalcification-associated breast cancer: HER2-enriched molecular subtype is associated with mammographic features. Br J Radiol. Forthcoming 2021. P. 29:20170942. DOI: 10.1259/bjr.20170942.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sturesdotter L, Sandsveden M, Johnson K, et al. Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype. Sci Rep. 2020;10(Suppl. 1):20814. DOI: 10.1038/s41598-020-77053-7.</mixed-citation><mixed-citation xml:lang="en">Sturesdotter L, Sandsveden M, Johnson K, et al. Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype. Sci Rep. 2020;10(Suppl. 1):20814. DOI: 10.1038/s41598-020-77053-7.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ryu MJ, Kim YS, Lee SE. Association Between Imaging Features Using the BI-RADS and Tumor Subtype in Patients with Invasive Breast Cancer. Curr Med Imaging. 2022;18(Suppl. 6):648-57. DOI: 10.2174/1573405617666210520155157.</mixed-citation><mixed-citation xml:lang="en">Ryu MJ, Kim YS, Lee SE. Association Between Imaging Features Using the BI-RADS and Tumor Subtype in Patients with Invasive Breast Cancer. Curr Med Imaging. 2022;18(Suppl. 6):648-57. DOI: 10.2174/1573405617666210520155157.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Davey MG, Davey MS, Boland MR, et al. Radiomic differentiation of breast cancer molecular subtypes using pre-operative breast imaging — A systematic review and meta-analysis. Eur J Radiol. 2021;144:109996. DOI: 10.1016/j.ejrad.2021.109996.</mixed-citation><mixed-citation xml:lang="en">Davey MG, Davey MS, Boland MR, et al. Radiomic differentiation of breast cancer molecular subtypes using pre-operative breast imaging — A systematic review and meta-analysis. Eur J Radiol. 2021;144:109996. DOI: 10.1016/j.ejrad.2021.109996.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
